Montelukast Junior Denk

Montelukast, the active ingredient in Montelukast Junior Denk, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, including exercise‑induced bronchoconstriction, and allergic rhinitis in children. GNH USA supplies Montelukast Junior Denk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic respiratory and allergic conditions. - Asthma: reduces the frequency and severity of bronchospasm and improves overall control. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes caused by allergen exposure.

Adverse reactions may occur with any medication and should be monitored.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Angioedema - Stevens‑Johnson syndrome - Anaphylaxis

Before prescribing Montelukast, clinicians should consider several safety aspects. - Assess asthma control: ensure the drug complements existing therapy. - Monitor for mood changes: watch for agitation, depression or suicidal thoughts. - Avoid in patients with known hypersensitivity to montelukast or any tablet excipients. - Use with caution in hepatic impairment: dose adjustment may be required. - Store at below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Ketoconazole: strong CYP3A4 inhibition can raise montelukast levels. - Itraconazole: similar CYP3A4 inhibition risk. - Ritonavir: potent CYP3A4 inhibitor may increase exposure.

Moderate Interactions (Monitor Closely): - Phenobarbital: enzyme induction may lower montelukast concentrations. - Rifampin: hepatic enzyme induction can reduce effectiveness. - Fluconazole: moderate CYP3A4 inhibition may modestly increase levels.